Home Biosimilar Antibodies NF-κB NF-κB -RANKL/RANK Denosumab (anti-RANK ligand)
For research use only. Not for use in humans.

Denosumab (anti-RANK ligand)

Synonyms: TNFSF11， CD254

Denosumab (anti-RANK ligand) (AMG-162) is a fully human monoclonal antibody that selectively inhibits primate RANKL. Denosumab inhibits the ability of human RANKL (143–317) to stimulate the formation of osteoclasts derived from murine RAW 264.7 cells with an IC50 value of 1.64 nM.

Denosumab (anti-RANK ligand)

Click to purchase the isotype control of Denosumab (anti-RANK ligand)

4 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99.68% Protein concentration: 5mg/ml Endotoxin Level: <1EU/mg
99.68

Specificity

Name Citation NF-κB Others
QNZ (EVP4593) 156 TNF-α
JSH-23 170
B022 0
UCB-9260 0 TNF
Morusin 0 STAT3
IQ 3 1 TNF-α,IL-6,JNK3
CBL0137 14 FACT,p53
NIK SMI1 0
Ginsenoside Rb3 1 iNOS,COX-2
Ginsenoside Rd 6 iNOS,COX-2,Ca2+ influx
CBL0137 Hydrochloride 11 FACT,p53
SC75741 53
TPCA-1 73 STAT3,IKK2
Bardoxolone Methyl (RTA 402) 36 IKK,Ferroptosis,Nrf2
Curcumin (Diferuloylmethane) 51 Nrf2,Ferroptosis,HDAC
Sodium 4-Aminosalicylate 2
Caffeic Acid Phenethyl Ester 58
Sodium salicylate 1
HOIPIN-8 2
EN450 0
Chitosan oligosaccharide 1
NF-κB-IN-1 3
SM-7368 0
sappanone A 1
Okanin 0 TLR4
Rubiadin 1-methyl ether 0
Cornuside 1
BTYNB 1
TCEP Hydrochloride 2
IMM-H007 0 ABCA1,JNK/AP1,AMPK
Urolithin B 1 ERK,JNK,IκBα
L-Quebrachitol 0 Wnt/β-catenin,MAPK,Runx2
Licochalcone D 1 EGFR,JAK2,PARP
Tectochrysin 0
Caulophylline (N-Methylcytisine) 0 IκB,MPO,IKK
Myrislignan 1 COX-2,iNOS,TNF-α
NDMC101 0
Gardenoside 1 IL-6,IL-1β,TNF-α
Cucurbitacin IIb 1 IκBα,ERK1/2,JNK
Jaceosidin 0 Mcl-1,Bax,COX-2
Isoliquiritin apioside 0 MAPK,MMP
Withaferin A (WFA) 13 vimentin
Rocaglamide 5 eIF4A,HSF1
Xanthatin 0 STATs
Alobresib (GS-5829) 0 MYC,ERK1/2,Akt
Adjudin 1 ERK,Cl⁻ channel
IAXO-102 1 MAPK,TLR4
C25-140 1 TRAF6-Ubc13
SN50 5
INH14 0 IKKβ,IKKα
TAK-243 (MLN7243) 78 UAE
Sulforaphane 23 Nrf2,HO-1,ROS
Madecassic acid 3 IL-1β,TNF-α,COX-2
Homoplantaginin 1 IL-6,IKKβ,TNF-α
(+)-Praeruptorin A 0
2',5'-Dihydroxyacetophenone 1 IL-6,TNF-α,ERK1/2
Dauricine 2
8-O-acetyl shanzhiside methyl ester 0
Forsythoside B 0 IκB,IL-6,TNF-alpha
Engeletin 2
Berbamine 10 CaMKII,Bcr-Abl
Eleutheroside E 1
Mulberroside A 0 Caspase-1,NALP3,IL-6
Maslinic acid 1
Chelidonic acid 0 glutamate decarboxylase,IL-6,Caspase-1
Hyperoside 5
Vanillic acid 0
4'-Hydroxychalcone 1
(+)-α-Lipoic acid 1 LTR
4-Hydroxychalcone 3
Neferine 6
Benfotiamine 1
Ginsenoside Rb1 4 IFN-β,TNF-α,TLR4
Ginsenoside Rg1 7 Aβ
Guaiacol 0 COX-2
(E)-Cardamonin 1 TRPA1
Hederagenin 0 COX-2,iNOS
Ginsenoside Re 2 JNK,Aβ
Scutellarin 3 Akt,STAT3
Mangiferin 2 Nrf2
Schisantherin A 0
Curcumenol 3 CYP3A4
Muscone 4 TNF-α,IL-1β,NLRP3 inflammasome
Tyrosol 0
Stachydrine 3
Sodium Aescinate 3
Dehydroevodiamine 0 PGE2,iNOS,COX-2
Astragaloside IV 6 mTOR,Akt,ERK
4'-Methoxyresveratrol 0 NLRP3
Berbamine dihydrochloride 4 CaMKII,Bcr-Abl
Sarsasapogenin 1 IκBα,TAK1,IRAK1
(Rac)-Shikonin 44 Proteasome,chemokine receptor,TNF-α
Diethylmaleate 0 Nrf2
Omaveloxolone (RTA-408) 11 Nrf2
DTP3 2 GADD45β/MKK7
APX-3330 6 APE1(Ref-1)
Triptolide 47 MDM2,HSF1
Methylthiouracil 1 ERK1/2,IL-6,TNF-α
Erdosteine 0
Evodiamine 9
Vanillylacetone 1
(-)-Parthenolide 28 p53,MDM2,HDAC1
Magnolol 7
Indole-3-carbinol 4
DHA (Dihydroartemisinin) 36
Andrographolide 16
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Denosumab (anti-RANK ligand) (AMG-162) is a fully human monoclonal antibody that selectively inhibits primate RANKL. Denosumab inhibits the ability of human RANKL (143–317) to stimulate the formation of osteoclasts derived from murine RAW 264.7 cells with an IC50 value of 1.64 nM.
References

Product Details

CAS No. 615258-40-7
Molecular Weight 145.16 kDa
Isotype human IgG2SA
Source HEK293
Sterility 0.2 μM filtered
Formulation PBS Buffer, pH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06374459 RECRUITING Drug: Zumsemetinib|Drug: Capecitabine|Drug: Zoledronic acid| Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer Washington University School of Medicine 2025-01-30 PHASE1; PHASE2
NCT06767150 RECRUITING Drug: a second infusion of ZOL when crosslaps levels reach 3 Postmenopausal Osteoporosis University Hospital, Toulouse 2025-10-02 PHASE4
NCT07406685 RECRUITING Drug: Ibandronate IV|Drug: Zoledronic acid IV Postmenopausal Osteoporosis; Postmenopausal Osteopenia; Primary Osteoporosis; Osteoporosis National Taiwan University Hospital 2026-08-20 PHASE4
NCT07772609 NOT_YET_RECRUITING Drug: Romosozumab|Drug: Zoledronic Acid 5 MG in 5 ML Injecti Osteoporosis in Post-menopausal Women Sahlgrenska University Hospital 2027-01-11 PHASE4
NCT07537972 NOT_YET_RECRUITING Drug: Denosumab|Drug: Sintilimab Hepatocellular Carcinoma (HCC); Bone Metastases Tongji Hospital 2026-05-01 PHASE2
NCT06938152 RECRUITING Drug: Romosozumab followed by Denosumab|Drug: Romosozumab an Osteoporosis; Osteoporosis Postmenopausal National Taiwan University Hospital 2025-04-08 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-04-20)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.